0R15 8884.0068 1.4156% 0R1E 9171.0 0.0% 0M69 None None% 0R2V 255.5 0.3929% 0QYR 1619.0 0.0% 0QYP 434.5 -0.344% 0RUK None None% 0RYA 1600.0 4.5752% 0RIH 195.2 1.3763% 0RIH 195.2 1.3763% 0R1O 225.5 9877.8761% 0R1O None None% 0QFP None None% 0M2Z 255.0 0.2457% 0VSO 33.3 -6.4738% 0R1I None None% 0QZI 596.0 0.0% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 236.3943 1.5483%
Oncimmune Holdings Plc (LON: ONC)
Oncimmune Holdings Plc is an FTSE AIM All-Share index listed cancer diagnosis company engaged in developing and commercializing its EarlyCDT platform technology. The Company operates in the United Kingdom, North America and the Rest of the world. It operates in the development of autoantibody tests, and EarlyCDT-Lung blood test. It is also developing the EarlyCDT tests for other cancers, including liver and ovarian cancers. It has sold more than 145,000 tests in the USA and the UK.
FY21 results are expected to be out by around September end.
Major Segments:
(Source: LSE Website)
Other developments throughout the year:
(Source: Company Presentation)
Growth Prospects
Key Risks
Now we will analyze some key fundamental and shareholders statistics of Oncimmune Holdings Plc.
FY21 Trading Update (released on 8 June 21)
Financial and Operational Highlights (for H1FY21 ended 30 November 2020 as of 15 February 2021)
(Source: LSE Website)
Share Price Performance Analysis
(Source: Refinitiv, Research done by Kalkine Group)
On 2 September 2021, at 8:30 AM GMT, ONC’s shares traded at GBX 185.20, down by 1.75% against the previous day closing price. ONC’s 52-week High and Low were GBX 261.63 and GBX 137.51, respectively.
On a daily chart, the stock price is sustaining around the 20-day EMA at about GBX 186.80. Hence, there could be an uptick in the stock price in the near term. Also, the stock is sustaining above the channel breakout, indicating a potential upside momentum in the near term.
ONC’s stock has delivered a decent positive return of ~97.38% in the last two years. Also, it has outperformed the FTSE AIM All-share Healthcare index with a return of about 47.04% and FTSE AIM All-Share Index with a return of about 49.30%.
.Valuation Methodology: EV/Sales Approach (NTM) (Illustrative)
Business Outlook
ONC delivered an excellent performance in FY21, with revenue growth of 8x against FY20. The Company's recent acquisition of IP could become the growth driver for the Company in the US capital market. Moreover, recent contracts from H4FY20 and H1FY21 would yield returns in FY22. The Company's recent success in the trial shows its R&D strength, and the pipeline of the portfolio could expand its reach in the UK and the US and across the globe.
Considering the Company’s product pipeline, recent success in trials, continued expansion strategy, and support from the valuation using the above method, we have given a “Speculative Buy” recommendation on Oncimmune Holdings Plc at the current price of GBX 185.20 (as on 2 September 2021, at 8:30 AM GMT), with a lower-double digit upside potential based on 12.89x EV/Sales (approx.) on FY22E sales (approx.)
*Depending upon the risk tolerance, investors may consider unwinding their positions in a respective stock once the estimated target price is reached. The recommended target is above the Resistance level 2 and if Oncimmune Holdings Plc attains momentum or breach it, then the target price as per the valuation table could be seen in the near term as per technical chart analysis.
*All forecasted figures and Peer information have been taken from Refinitiv.
*The reference data in this report has been partly sourced from Refinitiv.
Disclaimer
References to ‘Kalkine’, ‘we’, ‘our’ and ‘us’ refer to Kalkine Limited.
This website is a service of Kalkine Limited. Kalkine Limited is a private limited company, incorporated in England and Wales with registration number 07903332. Kalkine Limited is authorised and regulated by the Financial Conduct Authority under reference number 579414.
The article has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. No advice or information, whether oral or written, obtained by you from Kalkine or through or from the service shall create any warranty not expressly stated. Kalkine does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation.
Kalkine does not offer financial advice based upon your personal financial situation or goals, and we shall NOT be held liable for any investment or trading losses you may incur by using the opinions expressed in our publications, market updates, news alerts and corporate profiles. Kalkine does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation. Kalkine’s non-personalised advice does not in any way endorse or recommend individuals, investment products or services for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a professional authorised financial planner and adviser. You should be aware that the value of any investment and the income from it can go down as well as up and you may not get back the amount invested.
Kalkine Media Limited, an affiliate of Kalkine Limited, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.